People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Savran Technologies Inc. | — | Biotechnology | Series A | $6.2M | $2.1M | 2018 |
| AnTolRx, Inc. | — | Biotechnology | Pre-Seed | $1.0M | $55.2M | 2016 |
Mark Carthy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Carthy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Rivelli | 1 | 6 |
| Jeffrey Behrens | 1 | 3 |
| Simon W. Turner | 1 | 2 |
| Satish Jindal | 1 | 2 |
| Sal Daher | 1 | 1 |
| Yavuz Kaynar | 1 | 1 |
| Jeff Behrens | 1 | 1 |
| Saleh W. Daher | 1 | 1 |
| Francisco Quintana | 1 | 1 |
| Cagri Savran | 1 | 1 |
| Nadia Altomare | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.